-
Jul 18, 2024 | 
benzinga.com | Jeremy Golden
The artificial intelligence (AI) market, valued at more than $184 billion this year, is among the most groundbreaking tech segments of this generation. Search traffic volume for the keyword "AI" tripled over a one-year period from 2022 to 2023, with more than 30 million searches occurring during March 2023. This demonstrates the heightened appetite for artificial intelligence solutions. The AI market is projected to reach $407 billion by 2027.
-
Jun 14, 2024 | 
menafn.com | Jeremy Golden
Candel Therapeutics' (NASDAQ: CADL) Enlighten Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
6/14/2024 2:18:14 PM
(MENAFN- News Direct) --News Direct--By Jeremy Golden, Benzinga Candel Therapeutics, Inc. (NASDAQ: CADL) is helping pioneer the next generation of viral immunotherapy by leveraging a data-driven approach to create new assets and further the development of existing drug candidates.
-
Jun 13, 2024 | 
benzinga.com | Jeremy Golden
Candel Therapeutics, Inc. CADL is helping pioneer the next generation of viral immunotherapy by leveraging a data-driven approach to create new assets and further the development of existing drug candidates.
-
Jun 7, 2024 | 
wicz.com | Jeremy Golden
--News Direct--By Jeremy Golden, BenzingaImmunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments. Poor ICI treatment response has been linked to the tumor’s ability to disguise antigen presentation and generate an immunosuppressive microenvironment.
-
Jun 7, 2024 | 
nasdaq.com | Jeremy Golden
Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments. Poor ICI treatment response has been linked to the tumor’s ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patient’s immune system on how to recognize a variety of tumor antigens and neoantigens.
-
Jun 6, 2024 | 
benzinga.com | Jeremy Golden
Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments. Poor ICI treatment response has been linked to the tumor's ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patient's immune system on how to recognize a variety of tumor antigens and neoantigens.
-
Jun 3, 2024 | 
apnews.com | Jeremy Golden
By Jeremy Golden, BenzingaNEEDHAM, MA / ACCESSWIRE / June 3, 2024 / Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ:CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.
-
Jun 3, 2024 | 
nasdaq.com | Jeremy Golden
Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.
-
May 31, 2024 | 
benzinga.com | Jeremy Golden
Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. CADL reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023.
-
May 7, 2024 | 
marketscreener.com | Jeremy Golden
(via NewsDirect)By Jeremy Golden, BenzingaCardio Diagnostics(NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has announced the publication of results from a budget impact modeling study for one of its leading clinical products. PrecisionCHD is an integrated genetic-epigenetic test for the detection of coronary heart disease (CHD).
